Future projects
Topical rFVIIa/TF-complexing results in inhibition of all kinds of postpartum bleedings no matter their size or origin.
Through performance of randomized, controlled studies during vaginal delivery we hope to be able to reach women all over the world in the fight against postpartum bleedings by using simple tools: a sterile rolled gauze, dried rFVIIa and sterile saline.
We are looking for partners who produce and sell rFVIIa.
We are looking forward to working with large hospitals that can perform clinical trials.
Our goal is to obtain approval from European Medicines Agency and from the Food and Drug Administration in USA for topical rFVIIa to be used against postpartum hemorrhage.
Obstetric Facts
-
Delivery complements the biggest risk of death for a fertile woman, more than 300.000 women die each year. The majority lives in poor areas in Africa and Asia. Bleeding is the main cause
-
5-15 % of women in the developed world bleed more than the accepted 500 mL
-
6-7 % bleed more than 1000 mL, these numbers are far more critical in poor countries
-
Recombinant, activated Factor VII (rFVIIa) given intravenousely diminishes severe postpartum bleedings but puts women at risk of thrombotic events.
-
In theory topical rFVIIa on the placenta site will diminish postpartum bleedings since the concentration of tissue factor at the placenta site is very high
-
We aim to show a significant reduction of bleeding in randomized, controlled studies in women with bleedings after delivery with simple means that do not require intravenous access.
WE SPECIALIZE IN BLEEDINGS AFTER DELIVERY
High Risk Pregnancy
Placenta Previa
Normal pregnancy
Cesarean and vaginal delivery